Navigation Links
Medivation Announces Second Quarter 2010 Financial Results Teleconference and Webcast on August 9, 2010

SAN FRANCISCO, Aug. 2 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will host a teleconference and webcast with management to discuss second quarter 2010 financial results and provide a general business update on August 9, 2010, at 4:30 p.m. Eastern Time. A press release for the second quarter ended June 30, 2010 will be released after markets close on August 9, 2010.

Interested parties may call 877-303-2523 from the U.S. or +1-253-237-1755 internationally. Individuals interested in listening to the live call via webcast may do so by visiting A replay of the webcast will be available on the Company's website for 30 days.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer, Inc to develop and commercialize dimebon (latrepirdine) for the treatment of Alzheimer's and Huntington diseases. With Pfizer, Medivation is conducting a clinical development program that includes CONCERT, a Phase 3 trial assessing dimebon in patients with mild-to-moderate Alzheimer's disease, and HORIZON, a Phase 3 trial of dimebon in Huntington disease. In October 2009, Medivation entered into a global agreement with Astellas Pharma Inc. to develop and commercialize MDV3100 for both early- and late-stage prostate cancer. The first Phase 3 clinical trial in the MDV3100 development program, known as the AFFIRM trial, is under way in patients with castration-resistant prostate cancer who have previously been treated with docetaxel-based chemotherapy. Additional trials in earlier-stage prostate cancer will begin in 2010. For more information, please visit us at

SOURCE Medivation, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Medivation Announces Organizational Changes to Support Anticipated Growth and Future Commercialization
2. Medivation Reports Third Quarter 2009 Financial Results and Provides Corporate Update
3. Astellas and Medivation Enter Into Worldwide Agreement to Co-Develop and Co-Commercialize MDV3100 for the Treatment of Prostate Cancer
4. Medivation Announces Initiation of Phase 3 Clinical Trial of MDV3100 in Advanced Prostate Cancer
5. Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
6. Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimers Disease
7. Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
8. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
9. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
10. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
11. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
Post Your Comments:
(Date:10/13/2015)... SHANGHAI , Oct. 13, 2015 ... R&D capability and technology platform company serving the ... that it has launched a mobile version of ... allow researchers to access oncology models and data ... clients anywhere and at any time to identify ...
(Date:10/13/2015)... , Oct. 13, 2015  The ... Harvard University today announced the launch of ... Ultivue will introduce imaging reagents providing ... to those of expensive specialized instruments. The ... Harvard,s Office of Technology Development (OTD) ...
(Date:10/13/2015)... , October 13, 2015 --> ... ,What can be expected from the Asthma and COPD Therapies ... rates? Visiongain ,s brand new report shows you potential ... ,  ,Our 309-page report provides 260 tables, charts, and graphs. ... future market prospects. Our new study lets you assess forecasted ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... Purdue ... in the Life Sciences Initiative aimed at enhancing Purdue’s life sciences research and ... “Ever True” capital campaign. , The investment will result in cohesive efforts across ...
(Date:10/13/2015)... ... 2015 , ... Sir Grout of Greater Boston donated an expansive, seven room ... McDonald House Charities® (RMHC®). This donation was made in an effort to give back ... its inception. , “We believe strongly in the Ronald McDonald House Charities, and they ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... in the United States, today announced the release of its limited edition holiday ... Cranberry Cocktail Agua Fresca. All feature the unique flavor combinations and delicious taste ...
(Date:10/13/2015)... ... , ... According to an article published October 5th by the ... lose weight with a bariatric procedure are much less likely to develop endometrial cancer, ... anywhere from 40 to 50 percent of all endometrial cancer cases are caused by ...
(Date:10/13/2015)... , ... October 13, 2015 , ... Symposium Chairman, Dr. ... 19th annual Dallas Cosmetic Symposium to be held March 2nd and 3rd, 2016. The ... afterwards, draws plastic surgeons and cosmetic physicians from around the world. , Key topics ...
Breaking Medicine News(10 mins):